Scientific Sessions 2025  /  AF Lifestyle Therapy: Drugs Beyond Heart Failure and Obesity  /  SGLT2 inhibitors vs GLP 1 inhibitors for sleep apnea and atrial fibrillation
Logo

American Heart Association

  35
  0

Final ID:

SGLT2 inhibitors vs GLP 1 inhibitors for sleep apnea and atrial fibrillation

  • Dominic, Paari  ( LSUHSC Shreveport , Shreveport , Louisiana , United States )
  • Kalman, Jonathan  ( Department of Cardiology , Melbourne , Victoria , Australia )
    • Author Disclosures:
    Paari Dominic: No Answer | Jonathan Kalman: DO have relevant financial relationships ; Research Funding (PI or named investigator):Medtronic:Active (exists now) ; Research Funding (PI or named investigator):Boston Scientific:Expected (by end of conference) ; Research Funding (PI or named investigator):Zoll:Active (exists now) ; Other (please indicate in the box next to the company name):Johnson and Johnson Medtech-Research fellow support:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

AF Lifestyle Therapy: Drugs Beyond Heart Failure and Obesity

Friday, 11/07/2025 , 12:30PM - 01:45PM

Cardiovascular Seminar

More abstracts on this topic:
Icosapent Ethyl in Patients With and Without Atrial Fibrillation (REDUCE IT)

Olshansky Brian, Reiffel James

Atrial Fibrosis progression in sleep apnea patients: A pilot study (PROOF Study)

Marrouche Nassir

More abstracts from these authors:
Aggressive Risk factor REduction STudy for Atrial Fibrillation (ARREST-AF) implications for ablation outcomes: A Randomized Clinical Trial

Pathak Rajeev, Mahajan Rajiv, Abhayaratna Walter, Kalman Jonathan, Sanders Prashanthan, Elliott Adrian, Lau Dennis, Middeldorp Melissa, Linz Dominik, Fitzgerald John, Ariyaratnam Jonathan, Malik Varun, Noubiap Jean Jacques

You have to be authorized to contact abstract author. Please, Login
Not Available